anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A Chinese medicinal composition and its application in preparing medicine for treating diabetic foot are provided. The traditional Chinese medicine composition comprises the following components in parts by weight: 30-50 parts of radix sophorae flavescentis, 30-50 parts of Chinese lobelia, 30-50 parts of honeysuckle and 30-50 parts of rhizoma polygonati; the traditional Chinese medicine composition is prepared by dialectical compatibility of various traditional Chinese medicines and assists mutually, so that the formula is reasonable. The application of the traditional Chinese medicine composition in preparing the medicine for treating diabetic foot. The preparation form of the traditional Chinese medicine composition is foot bath bag or lotion. The administration form of the preparation is soaking administration. By adopting the lotion, the diabetic foot of a patient is subjected to foot bath, namely, the lotion is used for soaking feet and soaking corresponding lesion tissues for administration, so that active medicinal ingredients in the lotion can be intensively permeated into the lesion tissues in high concentration, and the lotion has the effects of clearing heat and removing toxicity, eliminating dampness and swelling, and removing putrefaction and promoting granulation on the lesion tissues.
Muscular dystrophies are caused by mutations in more than 30 genes, some of them remaining to be identified. Phenotypically, it is known that one specific mutation can affect the expression of several other proteins causing difficulty in diagnosis. Correct genotyping is essential for diagnosis, prognosis and treatment, and relies on a complexed analysis of muscle tissues for phenotype profiles. Our research aims to understand how different gene mutations affect expression of other genes via muscle biopsy samples and establishment of phenotypic profiles for correct diagnosis of individual patients. Establishment of such information will be critical for understanding the progression of different muscular dystrophies and to devise new experimental therapies. This research will also provide vital clues for finding new genes involved in the disease process. Muscle samples may also be used to establish cell cultures for testing drugs and new therapies relevant to the treatment of the muscular dystrophies.
Septic lung injury is an unmet clinical challenge due to its high mortality, and there is a lack of effective treatment. Accumulating evidence suggests that an uncontrolled pulmonary inflammatory response is important in the pathogenesis of lung injury in sepsis. Therefore, limiting excessive early inflammatory responses may be an effective strategy. We established a septic lung injury model using cecal ligation and puncture. Western blotting and immunofluorescence analyses were performed to assess the expression of PTP1B and endoplasmic reticulum (ER) stress and pyroptosis. Co-immunoprecipitation was used to analyze the binding of PTP1B and Src molecules. PTP1B is upregulated in both in vivo and in vitro models of septic lung injury. PTP1B directly binds to Src and aggravates inflammation by regulating the ER stress-pyroptosis axis. The inhibition of PTP1B alleviates inflammation and improves the prognosis of septic mice. Our study suggesting that PT1B inhibitors have clinical application value in the treatment of septic lung injury. This may provide a new strategy for the treatment of septic lung injury.
The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term. A group of children who were carried full-term will be matched for age, sex, and race and will be used for comparison. Extremely premature infants (born at \<28-30 weeks gestation) have lower antibody responses than full-term infants to several vaccines given at the postnatal ages recommended for full term infants. We propose to evaluate the immunogenicity of varicella and mumps-measles-rubella (MMR) vaccines in relatively healthy 15 month-old children born at \<29 weeks gestation. This is a phase IV, observational study with 2 study arms having 16 infants each. The first group will enroll infants 9-12 months old that were born premature (\<29 weeks gestation). The second group will be matched for sex, race, and postnatal age, but will have been full term (\>= 37 weeks gestation) at birth. Infants will be vaccinated at visit 1 and post-vaccine serology will drawn at visit 2 (4 to 6 weeks after visit 1).
The invention relates to a preparation method of a Chinese traditional medicine prescription fructus chebulae immaturus dripping pill. The preparation method is characterized by comprising the following steps of: melting a fructus chebulae immaturus extract product and a solid matrix into a turbid liquor, and dropping the turbid liquor into a condensate liquid to contract and condense into a solid state, so as to prepare the dripping pill. The fructus chebulae immaturus dripping pill has very short dissolution and diffusion time limit. The main drug is rapidly released from the solid dispersion and rapidly takes effect. The matrix is liposoluble and water soluble and can fully dissolve the main drug extract. In addition, as water-solubility of effective components in the main drug extract is increased, the effective components are easy to absorb by body and can be fully absorbed, which is beneficial to fully performing drug effect, raising bioavailability and enhancing curative effect. The dripping pill can be taken orally and also can be kept under tongue, is especially used to alleviate and eliminate pharyngeal acute symptoms, and is more applicable to be kept under tongue. The preparation method of the fructus chebulae immaturus dripping pill has advantages of simple equipment, simple technological operation and no discharge of ''three wastes (waste gas, waste water and industrial residue)'', can be used to save time and energy, reduce cost, and accords with technical requirements for energy saving and emission reduction.
According to grouping，patients were premeditated with injection of Propofol 1-2mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, propofol 0.5mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.
Individuals in this group will not receive any treatment. Evaluations will be made before treatment and after 8 weeks of treatment.
PURPOSE:To enable the automatic operation of plural synthesizing apparatuses of radioactive labeled compounds separately by single driving device, by selecting and decoding a required program from a plurality of different operation programs, and transmitting the signal corresponding to the program. CONSTITUTION:A plurality of different operation programs are stored in a plurality of memories 10a-10n. The memories are selected by the program selection switch 11, and the selected memory is connected to the computer 12. The operation program stored in the memory is inputted to the computer 12 by the operation starting command. The computer 12 decodes the program and outputs a signal correesponding to the operation program. A plurality of synthetic apparatuses 8a-8n producing different radioactive labeled compounds (e.g. <11>C-glucose, <11>C-methyl iodide, etc.) are operated automatically and independently by the signal outputted from the computer of the driving device 7.
It is intended to provide a gene which is expressed specifically in arteriosclerosis lesion, a polypeptide and utilization thereof. From arteriosclerosis lesion cells of an apolipoprotein E-lacking mouse (ApoE-knockout mouse), a novel gene expressed specifically in these cells is cloned. Further, a gene homologous to this gene is obtained from a normal tissue. By measuring the expression of the above gene in smooth muscle cells and the formation of a protein encoded by this gene, arteriosclerosis can be diagnosed and a preventive or a remedy for arteriosclerosis can be screened. Moreover, arteriosclerosis can be prevented or treated by inhibiting the expression of the gene in arteriosclerosis smooth muscle cells. By transferring the gene expressed in arteriosclerosis into smooth muscle cells, apoptosis can be induced in vascular cells and thus the onset of arteriosclerosis can be prevented.
All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
PURPOSE: Acute kidney injury (AKI) is characterized by reduced renal function, oxidative stress, inflammation, and renal fibrosis. CU06-1004, an endothelial cell dysfunction blocker, exhibits anti-inflammatory effects by reducing vascular permeability in pathological conditions. However, the potential effects of CU06-1004 on AKI have not been investigated. We investigated the renoprotective effect of CU06-1004 against oxidative stress, inflammation, and fibrotic changes in a folic acid-induced AKI model.
METHODS: AKI was induced by intraperitoneal injection of high dose (250 mg/kg) folic acid in mice. CU06-1004 was orally administered a low (10 mg/kg) or high dose (20 mg/kg).
RESULTS: CU06-1004 ameliorated folic acid-induced AKI by decreasing serum blood urea nitrogen and creatinine levels, mitigating histological abnormalities, and decreasing tubular injury markers such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in folic acid-induced AKI mice. Additionally, CU06-1004 alleviated folic acid-induced oxidative stress by reducing 4-hydroxynonenal and malondialdehyde levels. Furthermore, it attenuated macrophage infiltration and suppressed the expression of the proinflammatory factors, including tumor necrosis factor-α, intercellular adhesion molecule-1, and vascular cell adhesion protein-1. Moreover, CU06-1004 mitigated folic acid-induced tubulointerstitial fibrosis by decreasing α-smooth muscle actin and transforming growth factor-β expression.
CONCLUSION: These findings suggest CU06-1004 as a potential therapeutic agent for folic acid-induced AKI.
The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) Heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.
Accidential ingestion of large amounts of fluoride may result in acute burning of the mouth and sore tongue. Nausea, vomiting and diarrhea may occur soon after ingestion (within 30 minutes) and are accompanied by salvation, hematemesis and epigastric cramping and abdominal pain. These symptoms may persist for 24 hours. If less than 5 mg fluoride/kg of body weight (i.e. less than 2.3 mg fluoride/kg of body weight) have been ingested, induce emesis, give oral soluble calcium (e.g. milk, 5% calcium gluconate or calcium lactate solution) and immediately seek medical assistance. For accidental ingestion of more that 15 mg fluoride/kg of body weight (i.e. more than 6.9 mg fluoride/kg of body weight), induce vomiting and admit immediately to a hospital facility.
<P>PROBLEM TO BE SOLVED: To provide a bleaching agent containing an unsaturated fatty acid monoglyceride.  <P>SOLUTION: The unsaturated fatty acid monoglyceride comprises any one of three hydroxy groups of glycerol, which is bound with an unsaturated fatty acid by an ester bond. The bleaching agent containing the unsaturated fatty acid monoglyceride exhibits an excellent bleaching action and excellent stability. The unsaturated fatty acid monoglyceride may be extracted from whole or part of plant or prepared by an arbitrary reaction. An unsaturated fatty acid monoglyceride on the market may be used. The bleaching agent is applied to a cosmetic, a quasi-drug or a medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
During the evaluation period, the participants' musculoskeletal pain threshold and tolerance will be measured using an algometer, about trigger points on the identified muscles (rectus abdominis, quadratus lumborum, erector spinae, and tibialis anterior). A total of 40 women, aged 18-40, diagnosed with primary dysmenorrhea by a gynecologist, will be included in the study. The initial assessment of the participants will be conducted on their most painful days. Participants will be randomized into two groups: the myofascial release technique group (study group) and the placebo myofascial release technique group (control group). The interventions will be conducted over 10 sessions during one menstrual cycle, and all evaluations will be repeated after the treatment period. The study will be conducted as a double-blind trial, ensuring that both the evaluators and the patients are blind to the group assignments.
Immunotherapy based on nanoplatforms is a promising approach to treat cancer and infectious diseases, and it has achieved considerable progress in clinical practices. Cell membrane-based nanoplatforms endow nanoparticles with versatile characteristics, such as half-life extension, targeting ability, and immune-system regulation. However, monotypic cell membrane usually fails to provoke strong immune response for immunotherapy while maintaining good biosafety. The integration of different cell-membrane types provides a promising approach to construct multifunctional nanoplatforms for improved immunotherapeutic efficacy by enhancing immunogenicity or targeting function, evading immune clearance, or combining with other therapeutic modalities. In this review, the design principles, preparation strategies, and applications of hybrid cell membrane-based nanoplatforms for cancer and infection immunotherapy are first discussed. Furthermore, the challenges and prospects for the potential clinical translation of hybrid cell membrane-based nanoplatforms are discussed.
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.
The study is defined as prospective observational. The research project involves the recruitment prospectively for all consecutive patients aged between 45 and 75 years receiving a new diagnosis of diabetes, according to the criteria established by the American Diabetes Association (ADA) (fasting glucose greater than or equal 126 mg / dl, or random blood glucose greater than or equal to 200 mg / dl, or glycated hemoglobin greater than or equal to 6.25%). The recruitment will take place at the Sant'Andrea Hospital. The suitability of a subject to be included in the study will be evaluated by medical history, physical examination and any further investigations carried out by a medical researcher of the team, according to the inclusion and exclusion criteria. The research team will be multidisciplinary, translational, composed of medical specialists belonging to the departments of General Surgery, Internal Medicine, Diabetology and Occupational Medicine. An informed consent will be mandatory for the recruitment in the study. At recruitment Adrenomedullin serum levels will be recorded along with every relevant clinical and laboratory data. An annual telephone follow-up will be applied and if necessary the patient will benefit of an outpatient examination. A sample size of 440 patients will achieve 80% power to detect a statistically significant difference. The 3 years clinical follow-up will allow the detection of symptoms and signs that could be related to the presence of a pancreatic mass (jaundice, pain, weight loss), further investigations will follow in such cases to confirm Pancreatic cancer diagnosis and proceed to the treatment.
BACKGROUND: Accurate haemodynamic monitoring in the prehospital setting is essential. Non-invasive blood pressure measurement is susceptible to vibration and motion artefact, especially at extremes of hypotension and hypertension: invasive arterial blood pressure (IABP) monitoring is a potential solution. This study describes the largest series to date of cases of IABP monitoring being initiated prehospital.
METHODS: This retrospective observational study was conducted at East Anglian Air Ambulance (EAAA), a UK helicopter emergency medical service (HEMS). It included all patients attended by EAAA who underwent arterial catheterisation and initiation of IABP monitoring between 1st February 2015 and 20th April 2023. The following data were retrieved for all patients: sex; age; aetiology (medical cardiac arrest, other medical emergency, trauma); site of arterial cannulation; operator role (doctor/paramedic); time of insertion and, where applicable, times of pre-hospital emergency anaesthesia, and return of spontaneous circulation following cardiac arrest. Descriptive analyses were performed to characterise the sample.
RESULTS: 13,556 patients were attended: IABP monitoring was initiated in 1083 (8.0%) cases, with a median age 59 years, of which 70.8% were male. 546 cases were of medical cardiac arrest: in 22.4% of these IABP monitoring was initiated during cardiopulmonary resuscitation. 322 were trauma cases, and the remaining 215 were medical emergencies. The patients were critically unwell: 981 required intubation, of which 789 underwent prehospital emergency anaesthesia; 609 received vasoactive medication. In 424 cases IABP monitoring was instituted en route to hospital.
CONCLUSION: This study describes over 1000 cases of prehospital arterial catheterisation and IABP monitoring in a UK HEMS system and has demonstrated feasibility at scale. The high-fidelity of invasive arterial blood pressure monitoring with the additional benefit of arterial blood gas analysis presents an attractive translation of in-hospital critical care to the prehospital setting.
A method for preparing a contrast agent precursor is revealed. The method includes several steps. First dissolve di-tert-butyl 2,2′-(1,4,7-triazacyclononane-1,4-diyl)diacetate, benzyl-2-bromoacetate and an alkaline compound in a first solvent to perform a bimolecular nucleophilic substitution reaction and get a product. Then dissolve the product in a second solvent to get a solution and adjust the pH value of the solution. Next add an organic solvent when the solution becomes acid and then remove a first organic layer that contains the organic solvent. Adjust the solution to become an alkaline solution and add the organic solvent again to get a second organic layer containing the organic solvent. The second organic layer contains the final product, di-tert-butyl 2,2′-{7-[2-(benzyloxy)-2-oxyethyl-(1,4,7-triazacyclononane-1,4-diyl}-diacetate.
Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but devastating condition caused by bisphosphonates, receptor activator of nuclear factor kappa-B ligand inhibitors, anti-angiogenic medications, and disease-modifying antirheumatic drugs. While the clinical spectrum of MRONJ has a wide range, there is a subgroup of patients that do not improve with antibiotics and conservative surgical debridement resulting in pathologic fractures, draining fistulas, and/or osteomyelitis. For the severely affected individuals, the only cure is surgical resection with micro-vascular free flap reconstruction. The etiology of MRONJ is unknown because of the lack of understanding of the biological underpinnings of the disorder connected to the mechanisms of action of the various medications. This limited knowledge has resulted in the classification of patients by clinical presentation rather than underlying pathology. Therefore, the aim of this article is to present a mechanistic framework of MRONJ through the mevalonate pathway in the context of the medications that are known to induce it and explore potential novel therapeutics.
Memory deficits are a prevalent, bothersome, and potentially debilitating symptom for millions of breast cancer survivors (BCS). Evidence-based treatment is difficult because there has been little intervention research in this area. Memory training may be a viable treatment option for BCS in need. Therefore, the purpose of this study is to examine the acceptability, usefulness, and preliminary efficacy of the memory training intervention from the Advanced Cognitive Training in Vital Elderly (ACTIVE) trial, the largest controlled trial of cognitive interventions in the behavioral sciences. The memory training intervention will be compared to attention control and no-contact control groups. Specific aims are to (1) evaluate the acceptability and usefulness of the memory intervention in BCS and (2) establish preliminary efficacy of the ACTIVE memory training intervention relative to attention control and no-contact control conditions. Acceptability and usefulness will be assessed through self-report. Memory will be assessed through objective neuropsychological tests. A total of 108 eligible BCS will be randomized to memory training, attention control, or no-contact control. A blinded and trained tester will perform data collection and neuropsychological testing at three time points: baseline prior to the intervention, immediately post-intervention, and 2 months post-intervention. Findings will provide information about the acceptability, usefulness, and preliminary efficacy of the ACTIVE memory training intervention on memory performance in BCS. Positive results will lead to a larger, full-scale study to determine efficacy of memory training interventions for BCS. Nursing interventional research in this area is vital to the development of evidence-based interventions to address memory deficits in BCS.